Drug: Etoposide

Phase 2Small molecule

FFujian Cancer Hospital

Drug: Etoposide is one of 51 small molecule programs targeting Neoadjuvant Therapy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neoadjuvant TherapyNot yet recruiting

Neoadjuvant TherapyPhase 2

Not yet recruiting

Competition

Competitive Landscape

62 competitors in Neoadjuvant Therapy

#DrugCompanyPhaseTrials

Lenvima

Eisai

Phase 3

2 2

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

6 3

Paraplatin

AAvyxa

Phase 3

5 4

Tuoyi

CCoherus Oncology, Inc.

Phase 3

2 5

Keytruda

Merck & Co.

Phase 2

5 6

Albumin-Bound Paclitaxel

Bristol-Myers Squibb

Phase 3

1 7

Avastin

Roche

Phase 2

4 8

Beyfortus

BeiGene

Phase 2

4 9

Abraxane

Bristol-Myers Squibb

Phase 2

3 10

Tagrisso

AstraZeneca

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

Phase 2Not yet recruiting

Neoadjuvant Therapy

NCT07155122

Clinical

Trials by Indication[1]

Neoadjuvant Therapy1 trial

Efficacy and Safety of Serplulimab Combined With Etoposide and Cisplatin as Neoadjuvant Therapy in Limited-Stage Small-Cell Carcinoma of the Esophageal

Not yet recruiting·FFujian Cancer Hospital·Phase 2·NCT07155122·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Drug: Etoposide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Drug: Etoposide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Drug: Etoposide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fujian Cancer Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: FFujian Cancer Hospital

Drug: Etoposide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2030

Trials by Indication[1]

Neoadjuvant Therapy1 trial

References

Drug Info

Quick Facts

Related News